Efficacy, Safety, and Exploratory Prognostic Factors of TACE-HAIC Plus Lenvatinib with Tislelizumab or Nivolumab in Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study.
A combination therapy approach produced encouraging survival outcomes in patients with difficult-to-treat advanced liver cancer.
This PubMed record examines Efficacy, Safety, and Exploratory Prognostic Factors of TACE-HAIC Plus Lenvatinib with Tislelizumab or Nivolumab in Unresectable Hepatocellular Carcinoma: A Retrospective Cohort Study. It reports CONCLUSION: This combination regimen was associated with encouraging outcomes in a selected, high-risk uHCC cohort.
What the study was
- Study design
- Randomized controlled trial
- Population
- Human participants
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal of hepatocellular carcinoma
Why it surfaced
Randomized controlled trial; conservative rapid-triage score based on PubMed title, publication type, and abstract.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.